Lusaris Therapeutics Launches With $60 Million Series A Financing To Redefine The Treatment Of Severe Neuropsychiatric And Neurological Disorders
Amount Raised
$60 Million
Round Type
Series A
MorrisvilleHealthcareTherapeuticsDescription
Lusaris Therapeutics, a biotechnology company advancing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological conditions, launched today with a $60 million Series A financing. The company’s lead program, LSR-1019, is a best-in-class sublingual formulation of 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a fast-acting and rapidly clearing serotonergic psychedelic, in development for patients with treatment-resistant depression (TRD) and other severe neuropsychiatric disorders. RA Capital Management incubated Lusaris and led the Series A round with participation from leading healthcare investors including Venrock Healthcare Capital Partners, Deep Track Capital, Boxer Capital, and an additional undisclosed investor.
Quick answer
Lusaris Therapeutics raised $60 Million in a Series A round, dated November 2, 2022. Lusaris Therapeutics is based in Morrisville, North Carolina, United States.
- How much did Lusaris Therapeutics raise?
- Lusaris Therapeutics raised $60 Million in a Series A round on November 2, 2022.
- What does Lusaris Therapeutics do?
- Lusaris is a biotechnology company advancing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders.
- Where is Lusaris Therapeutics based and how big is it?
- Lusaris Therapeutics is based in Morrisville, North Carolina, United States.
Source: Fundz verified event record.
Who else raised in Healthcare and Therapeutics around the same time
Companies in the same sectors as Lusaris Therapeutics that raised within 45 days of this round, from Fundz verified event records.
- BehaVR raised an undisclosed amount (Series B) on December 13, 2022.
- NewcelX raised $10M on December 13, 2022.
- Solid Biosciences raised $9.2M on December 2, 2022.
- Parabilis Medicines raised $178M (Series D) on November 21, 2022.
- Parabilis Medicines raised $178M on November 17, 2022.
- Phio Pharmaceuticals raised $2K (Seed) on November 16, 2022.
Who to call at Lusaris Therapeutics, and when
A new round usually means Lusaris Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Lusaris Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Lusaris Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lusaris Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lusaris Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansLusaris Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.